title: Collagen V nasal tolerance in experimental model of systemic sclerosis.
abstract: Our aim was to study skin remodeling and autoantibody production in an experimental model of scleroderma (SSc), following nasal tolerance with human type V collagen (Col V). Female New Zealand rabbits (n = 12) were immunized with two doses of 1 mg/ml of Col V in complete Freund's adjuvant and additional two boosters in incomplete Freund's adjuvant to induce SSc. After 150 days, half of these immunized rabbits were submitted to type V collagen-induced tolerance receiving a daily nasal administration of 25 mug of Col V. Control animals (n = 6) were only submitted to type V collagen-induced tolerance. Serial skin biopsies were performed on days 0, 150 and 210, and stained with H&E, Masson's trichrome and Picrosirius for morphological and morphometric analysis. Types I, III and V collagen were identified by immunofluorescence. The animals' serum samples were collected to determine anti types I, III, IV and V collagen and antinuclear antibodies (ANA). Skin biopsies from immunized animals confirmed SSc morphology as previously described, such as progressive decrease of papillary dermis, appendages atrophy, increased type I, III and V collagen deposition. Rabbits with Col V-induced nasal tolerance showed reduction of skin involvement, with significant decrease of collagen amount. Humoral immune response did not change with nasal tolerance. Collagen V nasal tolerance promotes regression of skin remodeling process in an experimental model of SSc. We suggest that nasal tolerance with type V collagen can be a promising therapeutic option to treat scleroderma patients.
authors.affiliation: Discipline of Reumatology, Faculty of Medicine, University of São Paulo, Av. Dr. Arnaldo 455; cep-01246-903, São Paulo, SP, Brazil.
authors.forename: Ana Paula Pereira
authors.initials: AP
authors.lastname: Velosa
authors.forename: Walcy Rosolia
authors.initials: WR
authors.lastname: Teodoro
authors.forename: Cristiane Carla
authors.initials: CC
authors.lastname: de Oliveira
authors.forename: Antonio
authors.initials: A
authors.lastname: Dos Santos Filho
authors.forename: Rodnei Francisco
authors.initials: RF
authors.lastname: Moutinho
authors.forename: Angela Gomes
authors.initials: AG
authors.lastname: Santos
authors.forename: Margarete Borges Galhardo
authors.initials: MB
authors.lastname: Vendramini
authors.forename: Cleonice
authors.initials: C
authors.lastname: Bueno
authors.forename: Edwin Roger
authors.initials: ER
authors.lastname: Parra
authors.forename: Vera Luiza
authors.initials: VL
authors.lastname: Capelozzi
authors.forename: Natalino Hajime
authors.initials: NH
authors.lastname: Yoshinari
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D000974:Antibodies, Antinuclear / Q000276:immunology / Q000378:metabolism; D001706:Biopsy; D003094:Collagen / Q000276:immunology / Q000378:metabolism; D024062:Collagen Type V / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D011817:Rabbits; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D012867:Skin / Q000378:metabolism / Q000473:pathology
chemical_list: D000906:Antibodies; D000974:Antibodies, Antinuclear; D024062:Collagen Type V; D003094:Collagen